# Claroty

publishes a documented case study of an Italian pharmaceutical multinational securing critical production plans and maintaining regulatory compliance without interrupting production, alongside dedicated guidance on securing OT in pharmaceutical and biotechnology.


Source: https://en.bioecon.ru/companies/claroty/
Updated: 2026-08-15

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | 510.1 million Euros in 2024 | https://blog.claroty.com/resources/case-studies/a-prescription-for-protection, https://claroty.com/resources/case-studies/a-prescription-for-protection, https://it.claroty.com/resources/case-studies/a-prescription-for-protection, https://social.claroty.com/resources/case-studies/a-prescription-for-protection, https://www.casestudies.com/company/claroty/case-study/fidia-farmaceutici-secures-1700-employee-operations-with-claroty-and-3-year-nis2-readiness |
| Capacity | 50 million/year, 115 million/year, 6 million/year, 75 million/year, 20 million patches/year, 35+ million towels/year, 3+ million lip sticks/year | https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Certification | ISO 14001, ISO 9001, ISO 13485, GMP, ISO 22716 | https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Regulatory approval | Authorized by AIFA | https://claroty.com/resources/case-studies/a-prescription-for-protection, https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Production site | Abano Terme (Padua), Noto (Syracuse), Paderno Dugnano (Milan), Monte Giberto (Fermo) | https://www.fidiapharma.com/our-innovation/sites/, https://www.fidiapharma.com/wp-content/uploads/2025/05/Fidia-Consolidated-financial-statements-2024.pdf |
| Headcount | 1,700 employees worldwide | https://blog.claroty.com/resources/case-studies/a-prescription-for-protection, https://claroty.com/resources/case-studies/a-prescription-for-protection, https://it.claroty.com/resources/case-studies/a-prescription-for-protection, https://social.claroty.com/resources/case-studies/a-prescription-for-protection, https://www.casestudies.com/company/claroty/case-study/fidia-farmaceutici-secures-1700-employee-operations-with-claroty-and-3-year-nis2-readiness, https://www.fidiapharma.ro/wp-content/uploads/2024/06/Corporate_Press_kit_ENG_MAY2024.pdf |
| Revenue | 510.1 million Euros in 2024 | https://blog.claroty.com/resources/case-studies/a-prescription-for-protection, https://claroty.com/resources/case-studies/a-prescription-for-protection, https://it.claroty.com/resources/case-studies/a-prescription-for-protection, https://social.claroty.com/resources/case-studies/a-prescription-for-protection, https://www.fidiapharma.ro/wp-content/uploads/2024/06/Corporate_Press_kit_ENG_MAY2024.pdf |

Independent sources: casestudies.com, fidiapharma.com, fidiapharma.ro

## Technologies

- [Bio-cybersecurity](https://en.bioecon.ru/technology/bio-cybersecurity/)